{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:27:46Z","timestamp":1790663266429,"version":"4.1.0"},"reference-count":24,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,10,15]]},"DOI":"10.18632\/oncotarget.1925","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:37:56Z","timestamp":1442360276000},"page":"9033-9038","source":"Crossref","is-referenced-by-count":59,"title":["The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors"],"prefix":"10.18632","volume":"5","author":[{"given":"Tun Kiat","family":"Ko","sequence":"first","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.H.","family":"Chuah","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Department of Haematology, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King-Pan","family":"Ng","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Tiong","family":"Ong","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Department of Haematology, Singapore General Hospital, Singapore"},{"name":"Department of Medical Oncology, National Cancer Centre, Singapore"},{"name":"Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,4,27]]},"reference":[{"issue":"23","key":"1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Reiffers","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"12","key":"2","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Forman","year":"2003","journal-title":"Blood"},{"issue":"11","key":"3","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Holyoake","year":"2006","journal-title":"Blood"},{"issue":"3","key":"4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Jordan","year":"2013","journal-title":"Cell stem cell"},{"issue":"3","key":"5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Chuang","year":"2013","journal-title":"Cell stem cell"},{"issue":"2","key":"6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Maekawa","year":"2008","journal-title":"British journal of haematology"},{"issue":"4","key":"7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Nagarajan","year":"2012","journal-title":"Nature medicine"},{"issue":"5","key":"8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib","volume":"40","author":"Belloc","year":"2012","journal-title":"Experimental hematology"},{"issue":"4","key":"9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Carter","year":"2012","journal-title":"Leukemia"},{"issue":"7042","key":"10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Li","year":"2005","journal-title":"Nature"},{"issue":"9","key":"11","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Fesik","year":"2008","journal-title":"Cancer research"},{"issue":"12","key":"12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Enschede","year":"2010","journal-title":"The lancet oncology"},{"issue":"5","key":"13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Tse","year":"2007","journal-title":"Cell death and differentiation"},{"issue":"6","key":"14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Kile","year":"2007","journal-title":"Cell"},{"issue":"2","key":"15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Lam","year":"2013","journal-title":"Nature medicine"},{"issue":"6","key":"16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the BCR-ABL1 kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Fernandez-Luna","year":"2000","journal-title":"The Journal of experimental medicine"},{"issue":"8","key":"17","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Sillaber","year":"2005","journal-title":"Blood"},{"issue":"12","key":"18","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","article-title":"Tumorigenic activity of the BCR-ABL1 oncogenes is mediated by BCL2","volume":"92","author":"Grutz","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL1 positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"issue":"5","key":"20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Capdeville","year":"2004","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/toxsci\/kfg188","article-title":"Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics","volume":"75","author":"Gribaldo","year":"2003","journal-title":"Toxicological sciences: an official journal of the Society of Toxicology"},{"issue":"s1","key":"22","first-page":"473","article-title":"The BCL-2 inhibitor ABT-199 (GDC-0199) is active and well-tolerated in ultra high-risk relapsed\/refractory chronic lymphocytic leukemia (CLL) [abstract]","volume":"98","author":"Graham","year":"2013","journal-title":"Haematologica"},{"issue":"s1","key":"23","first-page":"355","article-title":"The BCL-2 inhibitor ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed\/refractory mantle cell lymphoma and other non-hodgkin lymphomas [abstract]","volume":"98","author":"Enschede","year":"2013","journal-title":"Haematologica"},{"issue":"25","key":"24","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Ong","year":"2013","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:24:30Z","timestamp":1748625870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,27]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,10,15]]}},"alternative-id":["1925","25333252"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.1925","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,27]]}}}